teneligliptin
Trade name: Tenelia
Small moleculeexperimental
Clinical trial activity
28 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
15
Phase 3
14
Phase 4
7
Earliest trial started Jan 1, 2008 (NCT00628212)
Timeline
Indications
Approved for
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1- Mol. weight
- 426.59 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2147777 ↗
Also known as
- 3-(4-(4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
- tenelia
- teneligliptin
- teneligliptin
- teneligliptin
- teneligliptin
- teneligliptin
- teneligliptin
- teneligliptin
- teneligliptin
- teneligliptin hydrobromide
- teneligliptin hydrobromide hydrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07102719 | Phase 1 | Sep 30, 2025 | Handok Pharmaceuticals Co., Ltd. |
| NCT06889350 | Phase 1 | Mar 26, 2025 | Handok Pharmaceuticals Co., Ltd. |
| NCT06339788 | Phase 1 | Apr 30, 2024 | Handok Pharmaceuticals Co., Ltd. |
| NCT05504226 | Phase 3 | Oct 31, 2022 | Handok Pharmaceuticals Co., Ltd. |
| NCT05504239 | Phase 3 | Oct 31, 2022 | Handok Pharmaceuticals Co., Ltd. |
| NCT04431141 | Phase 1 | Jul 31, 2020 | Handok Pharmaceuticals Co., Ltd. |
| NCT04446026 | Phase 4 | Jul 8, 2020 | Yonsei University |
| NCT03769870 | Phase 1 | Jan 11, 2019 | Handok Pharmaceuticals Co., Ltd. |
| NCT03508323 | Phase 4 | Apr 3, 2018 | Handok Pharmaceuticals Co., Ltd., Sungkyunkwan University |
| NCT03014479 | Phase 4 | Jan 12, 2017 | Takeda |
| NCT03011177 | Phase 4 | Jan 1, 2017 | Handok Pharmaceuticals Co., Ltd. |
| NCT03009513 | Phase 1 | Jan 1, 2017 | Handok Pharmaceuticals Co., Ltd. |
| NCT02916706 | Phase 3 | Sep 1, 2016 | Mitsubishi Tanabe |
| NCT02924064 | Phase 3 | Sep 1, 2016 | Mitsubishi Tanabe |
| NCT02512523 | Phase 4 | Aug 1, 2015 | Handok Pharmaceuticals Co., Ltd., Korea University |
| NCT02449330 | Phase 4 | Jun 1, 2015 | National Cerebral and Cardiovascular Center |
| NCT02354222 | Phase 3 | Jan 1, 2015 | Mitsubishi Tanabe, University of Tokyo |
| NCT02567994 | Phase 3 | Jan 1, 2015 | Handok Pharmaceuticals Co., Ltd. |
| NCT02354235 | Phase 3 | Jan 1, 2015 | Mitsubishi Tanabe, University of Tokyo |
| NCT02220907 | Phase 3 | Aug 1, 2014 | Kyoto University, Mitsubishi Tanabe, University of Tokyo |
Showing 20 of 28 trials
Page 1 / 2
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Handok Pharmaceuticals Co., Ltd. | For profit | 13 | 13 | 3 | 2012 |
| Mitsubishi Tanabe | For profit | 12 | 12 | 3 | 2008 |
| University of Tokyo | Academic/Hospital | 10 | 0 | 3 | 2008 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Kyoto University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| National Cerebral and Cardiovascular Center | Government | 1 | 1 | 1 | 2015 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Takeda | For profit | 1 | 1 | 1 | 2017 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2020 |
10 organizations
Page 1 / 1